TYVASO DPI IS NOW APPROVED

Skip to main content

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Skip to main content

WHAT IS TYVASO?

TYVASO significantly increases your exercise capacity so you can be more active with your family and friends. It also reduces the risk of PH-ILD getting worse.

TYVASO is the first and only FDA-approved medication that can treat PH-ILD.

TYVASO can make a difference in what you can do every day

Treating PH-ILD right away can be a step forward for your health—and may help you do more in the moments that matter most.

In a clinical study, people who had PH-ILD and took TYVASO walked farther and had a significantly lower risk of getting worse.

TYVASO was also shown to help reduce strain on the heart. TYVASO helps keep the blood vessels in your lungs open so that your heart can pump blood more easily.

What about side effects?

In the clinical study, the side effects were generally mild or moderate. The most common were cough, headache, and throat irritation/pain.